Dementia and Movement Disorders

References

1. ↵
   McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–44

   Abstract/FREE Full Text
2. ↵
   Jagust WJ, Eberling JL. MRI, CT, SPECT, PET: their use in diagnosing dementia. Geriatrics 1991;46:28–35

   PubMed
3. ↵
   Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet 2006;367:1262–70

   CrossRefPubMedWeb of Science
4. ↵
   Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238–48

   Abstract/FREE Full Text
5. ↵
   Lehericy S, Baulac M, Chiras J, et al. Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease. AJNR Am J Neuroradiol 1994;15:929–37

   Abstract/FREE Full Text
6. ↵
   Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143–53

   Abstract/FREE Full Text
7. ↵
   Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001;56:592–08

   Abstract/FREE Full Text
8. ↵
   Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–19

   CrossRefPubMedWeb of Science
9. ↵
   McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001;58:1803–09

   CrossRefPubMedWeb of Science
10. ↵
    Heiss WD, Kessler J, Szelies B, Grond M, Fink G, Herholz K. Positron emission tomography in the differential diagnosis of organic dementias. J Neural Transm Suppl 1991;33:13–09

    PubMed
11. ↵
    Habert MO, Spampinato U, Mas JL, et al. A comparative technetium 99m hexamethylpropylene amine oxime SPET study in different types of dementia. Eur J Nucl Med 1991;18:3–11

    PubMedWeb of Science
12. ↵
    O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919–25

    CrossRefPubMedWeb of Science
13. ↵
    McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–72

    Abstract/FREE Full Text
14. ↵
    van Straaten EC, Scheltens P, Knol DL, et al. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke 2003;34:1907–12

    Abstract/FREE Full Text
15. ↵
    Singhal S, Rich P, Markus HS. The spatial distribution of MR imaging abnormalities in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and their relationship to age and clinical features. AJNR Am J Neuroradiol 2005;26:2481–07

    Abstract/FREE Full Text
16. ↵
    Kallenberg K, Schulz-Schaeffer WJ, Jastrow U, et al. Creutzfeldt-Jakob disease: comparative analysis of MR imaging sequences. AJNR Am J Neuroradiol 2006;27:1459–62

    Abstract/FREE Full Text
17. ↵
    Tschampa HJ, Kallenberg K, Urbach H, et al. MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain 2005;128:2026–33

    Abstract/FREE Full Text
18. ↵
    Zeidler M, Sellar RJ, Collie DA, et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 2000;355:1412–08

    CrossRefPubMedWeb of Science
19. ↵
    Larsson A, Arlig A, Bergh AC, et al. Quantitative SPECT cisternography in normal pressure hydrocephalus. Acta Neurol Scand 1994;90:190–06

    PubMed
20. ↵
    Vanneste J, Augustijn P, Tan WF, Dirven C. Shunting normal pressure hydrocephalus: the predictive value of combined clinical and CT data. J Neurol Neurosurg Psychiatry 1993;56:251–06

    Abstract/FREE Full Text
21. ↵
    Bradley WG, Jr., Whittemore AR, Kortman KE, et al. Marked cerebrospinal fluid void: indicator of successful shunt in patients with suspected normal-pressure hydrocephalus. Radiology 1991;178:459–66

    PubMedWeb of Science
22. ↵
    Simmons JT, Pastakia B, Chase TN, Shults CW. Magnetic resonance imaging in Huntington disease. AJNR Am J Neuroradiol 1986;7:25–08

    Abstract/FREE Full Text
23. ↵
    Drayer BP. Magnetic resonance imaging and extrapyramidal movement disorders. Eur Neurol 1989;29 Suppl 1:9–12
24. ↵
    Hayflick SJ, Hartman M, Coryell J, Gitschier J, Rowley H. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 2006;27:1230–03

    Abstract/FREE Full Text
25. ↵
    Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003;348:33–40

    CrossRefPubMedWeb of Science
26. ↵
    Sethi KD, Adams RJ, Loring DW, el Gammal T. Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol 1988;24:692–04

    CrossRefPubMedWeb of Science
27. ↵
    Stern MB, Braffman BH, Skolnick BE, Hurtig HI, Grossman RI. Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes. Neurology 1989;39:1524–06

    Abstract/FREE Full Text
28. ↵
    Bhattacharya K, Saadia D, Eisenkraft B, et al. Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm. Arch Neurol 2002;59:835–42

    CrossRefPubMedWeb of Science
29. ↵
    Bowen BC, Block RE, Sanchez-Ramos J, et al. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am J Neuroradiol 1995;16:61–08

    Abstract
30. ↵
    Brooks DJ. Advances in imaging Parkinson's disease. Curr Opin Neurol 1997;10:327–31

    PubMedWeb of Science
31. ↵
    Brown RT, Polinsky RJ, Di Chiro G, Pastakia B, Wener L, Simmons JT. MRI in autonomic failure. J Neurol Neurosurg Psychiatry 1987;50:913–04

    Abstract/FREE Full Text
32. ↵
    Otsuka M, Kuwabara Y, Ichiya Y, et al. Differentiating between multiple system atrophy and Parkinson's disease by positron emission tomography with 18F-dopa and 18F-FDG. Ann Nucl Med 1997;11:251–07

    PubMed
33. ↵
    Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002;125:1070–83

    Abstract/FREE Full Text
34. ↵
    Savoiardo M, Strada L, Girotti F, et al. MR imaging in progressive supranuclear palsy and Shy-Drager syndrome. J Comput Assist Tomogr 1989;13:555–60

    PubMedWeb of Science
35. ↵
    Goodin DS, Rowley HA, Olney RK. Magnetic resonance imaging in amyotrophic lateral sclerosis. Ann Neurol 1988;23:418–20

    CrossRefPubMedWeb of Science
36. ↵
    Hecht MJ, Fellner F, Fellner C, Hilz MJ, Neundorfer B, Heuss D. Hyperintense and hypointense MRI signals of the precentral gyrus and corticospinal tract in ALS: a follow-up examination including FLAIR images. J Neurol Sci 2002;199:59–65

    CrossRefPubMed
37. ↵
    Pioro EP. MR spectroscopy in amyotrophic lateral sclerosis/motor neuron disease. J Neurol Sci 1997;152 Suppl 1:S49–53
38. ↵
    Sach M, Winkler G, Glauche V, et al. Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain 2004;127:340–50

    Abstract/FREE Full Text